TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 years with diabetic macular edema~* Diagnosis of diabetes mellitus types 1 or 2~* Best corrected visual acuity of 19-68 letters~* Retinal thickness \> 250 micron by OCT~* Investigator is comfortable deferring macular laser treatment for 6 weeks~Exclusion Criteria:~* Glaucoma, ocular hypertension, IOP \>21 mmHg or concurrent therapy at screening with IOP lowering agents~* Retinal or choroidal neovascularization due to ocular conditions other than diabetic retinopathy~* Prior intravitreal, subtenon, or periocular steroid therapy within 6 months~* Any ocular surgery within the last 3 months~* Retinal laser treatment within the last 3 months~* History of uncontrolled IOP elevation with steroid use that did not respond to topical therapy~* Any lens opacity which impairs visualization of the posterior pole

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Ibandronate in Diabetic Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age of at least 55 years at the time of screening~* postmenopausal woman~* diagnosis of osteoporosis~Exclusion Criteria:~* history of osteoporosis treatment~* underlying disease (e.g., heart failure, liver disease, renal disease, or malignancy)~* the use of drugs that affect bone metabolism (e.g., steroids, immunosuppressants, gonadotropin-releasing hormone agonists, aromatase inhibitors, thiazolidinedione drugs, anticonvulsants, and antidepressants)~* history of adverse effects of bisphosphonate or difficulty taking the drug due to an inability to sit or the presence of upper gastrointestinal disease

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non-diabetes (Type: ACTIVE_COMPARATOR): postmenopausal women with normal glucose tolerance
- diabetes (Type: EXPERIMENTAL): postmenopausal women with type 2 diabetes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telavancin Observational Use Registry (TOUR)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~-received at least 1 dose of telavancin since January 1, 2015~Exclusion Criteria:~* Participation in an interventional research study or clinical trial involving telavancin after January 01, 2015

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vibativ (Type: None): This is an observational study for patients who were already prescribed Vibativ.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of High-dose Zinc Therapy and Albendazole in the Treatment of Environmental Enteropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 1-3 years of age~* Lives in study villages~Exclusion Criteria:~* Unable to drink 100 mL of sugar water~* Demonstrating evidence of severe acute malnutrition, WHZ \< or = -3, presence of bi-pedal pitting edema~* Apparent need for acute medical treatment for an illness or injury~* Parent refusal to participate and return for 7-week follow-up

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 3 Years
- Healthy Volunteers: t

Study Arms:
- Zinc therapy (Type: EXPERIMENTAL): High-dose zinc, equivalent 20 mg elemental zinc, to be given once per day for 14 days
- Albendazole (Type: EXPERIMENTAL): Albendazole to be given once on the day of enrollment. Placebo will then be given for 13 days following.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be given for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: between 50-80 years.~* Primary TKA surgery.~Exclusion Criteria:~1. Previous TKA and/or total hip arthroplasty surgery (older subjects).~2. Dementia or related mental issues that may potentially put the subject at risk as determined by the surgeon.~3. Untreated endocrine disease (Hypo/Hyperthyroidism, Addison's or Cushing's syndrome, etc.).~4. Significant heart, liver, kidney, blood, or respiratory disease.~5. Peripheral vascular disease.~6. Active cancer.~7. Recent (within 6 months) treatment with anabolic steroids.~8. Alcohol or drug abuse.~9. Inability to have MRI

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Essential Amino Acids (EAA) (Type: EXPERIMENTAL): Aim 1: Twice-daily ingestion of 20 g of EAA for 1 wk before through 6 wk after TKA.~Supplement composition for the EAAs: histidine, 2.2 g (11% of total); isoleucine, 2.0 g (10%); leucine, 3.6 g (18%); lysine, 3.2 g (16%); methionine, 0.6 g (3%); phenylalanine, 3.2 g (16%); threonine, 2.8 g (14%); and valine, 2.4 g (12%).~Aim 2: Twice-daily ingestion of 23 g of EAA for 1 wk before through 6 wk after TKA.~Supplement composition for the EAAs: histidine, 1.28 g (5% of total); isoleucine, 1.8 g (8%); leucine, 7.4 g (32%); lysine, 3.6 g (15%); methionine, 1.76 g (8%); phenylalanine, 3.1 g (13%); threonine, 1.9 g (8%); valine, 2.08 g (9%); and tryptophan, 0.5 g (2%).
- Placebo (Alanine) (Type: PLACEBO_COMPARATOR): Aim 1: Twice-daily ingestion of 20 g of Alanine (Non-essential amino acid) for 1 wk before through 6 wk after TKA.~The placebo supplement consists of 20 g (100%) alanine.~Aim 2: Twice-daily ingestion of 23 g of Alanine (Non-essential amino acid) for 1 wk before through 6 wk after TKA.~The placebo supplement consists of 23 g (100%) alanine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigating Accelerated Learning and Memory in Healthy Subjects Using a Face Name Memory Task

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-35 years~* Native English Speaker~Exclusion Criteria:~* History of severe head injuries, epileptic insults, or heart disease.~* Severe psychiatric disorders and severe untreated medical problems.~* Contraindications for tDCS (pregnant women, implanted devices)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- active tDCS (Type: EXPERIMENTAL): active tDCS with Face Name associate Memory task
- sham tDCS (Type: SHAM_COMPARATOR): sham tDCS with Face Name associate Memory task

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Cell Therapy for Treatment of Fecal Incontinence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary symptoms of fecal incontinence, as confirmed by patient medical history and physical examination~* Wexner (Cleveland Clinic Incontinence Severity (CCIS)) score ≥ 9~* Etiology of fecal incontinence is related, at least in part, to external anal sphincter dysfunction~* Failed conservative treatment~Exclusion Criteria:~* Gracilis sling repair or insertion of an artificial sphincter~* Inflammatory Bowel Disease~* Significant rectocele or rectal prolapse~* History of radiation treatment to the anal sphincter or adjacent structures~* Less than 18 years of age~* Pregnant, breastfeeding, or plans to become pregnant during the course of the study~* Neuromuscular disorder~* History of neoplasia within 5 years prior to enrollment, except for basal cell carcinoma, or is receiving or planning to receive anti-cancer medications~* Known bleeding diathesis or uncorrected coagulopathy~* Medical condition that would preclude treatment due to contraindications and/or warnings of concomitant medications or listed in the experimental product labeling~* Compromised immune system due to disease state, chronic corticosteroid use, or other immunosuppressive therapy~* Participating in another investigational drug or device study~* Unable or unwilling to provide informed consent~* Unable or unwilling to commit to the follow-up procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iltamiocel (Type: EXPERIMENTAL): AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intrasphincteric injection of 250 x 10\^6 cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study to Assess Lacosamide Safety as Add-on Therapy for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a diagnosis of uncontrolled epilepsy with primary generalized tonic-clonic (PGTC) seizures and idiopathic generalized epilepsy. Diagnosis should have been established by an electroencephalogram (EEG) with generalized spike-wave discharges within 5 years of the screening visit~* Subject has ≥1 PGTC seizure within the 12 weeks prior to the screening visit~* Subject has a stable dose regimen of 1 to 3 marketed antiepileptic drug(s) (AEDs) with or without additional concurrent stable Vagus Nerve Stimulation (VNS). The VNS must have been in place for at least 6 months prior to study entry with constant settings for at least 28 days prior to the screening visit and during the Baseline Phase. Benzodiazepines will be counted as an AED~Exclusion Criteria:~* Subject has a history of partial-onset seizures or EEG findings consistent with partial onset seizures~* Subject has a history of status epilepticus within the 5-year Period prior to Visit 1~* Subject has a current or previous diagnosis of pseudoseizures, conversion disorders, or other non-epileptic ictal events~* Subject has any medical or psychiatric condition~* Subject has any history of alcohol or drug abuse~* Subject is currently taking felbamate~* Subject has ever taken vigabatrin and has no visual fields examination report available or if results of the examination are abnormal~* Subject is on a ketogenic diet~* Subject has a known sodium channelopathy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ICG-PDT, Periimplantitis, Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
* Inclusion Criteria:~  * adult patients above 45 years of age having type 2 DM~ * HbA1c (≥6.5%) and fasting glucose test~ * probing depth ≥6 mm with bleeding and/or suppuration on at least one site around dental implants that remained in situ~ * On radiographic assessment, the implants exhibited ≥ 3 mm alveolar bone loss apical to the coronal region of the intraosteal portion of the dental implant.~* Exclusion Criteria Patients were excluded if they indicated current or former history of tobacco smoking, any systemic disease other than DM, enrolled in a non-surgical periodontal maintenance program, history of implant repair, pregnancy, and part six months use of antimicrobials, non-steroidal anti-inflammatory drugs, bisphosphonates, or corticosteroids.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Indocyanine green mediated photodynamic therapy (ICG-PDT) (Type: EXPERIMENTAL): Delivery of ICG solution at a concentration of 1 mg/mL will be used. The photosensitizer will be applied until the bottom of the peri-implant pocket using a 1 ml syringe. An 810 nm diode laser (A.R.C. laser GmbH, Nurnberg, Germany) with a power of 200 mW (continuous mode) and total energy of 4 J will be used to excite the ICG by starting from the papilla for 30 s followed by the insertion inside the peri-implant pocket depth for 10 s from both buccal and lingual side moving to coronal direction.
- Peri-implant mechanical debridement (Type: PLACEBO_COMPARATOR): Non-surgical peri-implant mechanical debridement (PIMD) through ultrasonic device with a carbon tip.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Short-term Growth Hormone in HIV-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* previously diagnosed HIV infection~* Stable antiretroviral regimen for at least 12 weeks prior to enrollment~* Waist circumference \>/= 95cm and waist-to-hip ratio \>/= 0.94 for males or waist circumference \>/=94cm and WHR \>/= 0.88 for females, occurring in the context of treatment for HIV disease~* Subjective evidence of at least one of the following changes, occurring during the treatment of HIV disease: increased abdominal girth, relative loss of fat in the extremities, or relative loss of fat in the face~Exclusion Criteria:~* Use of anti-diabetic agents, Megace, testosterone, or any steroid use within 6 months of the study~* Use of GH or Growth hormone releasing factor within six months of starting the study~* Change in lipid lowering or antihypertensive regimen within 3 months of screening~* Fasting blood sugar \>126mg/dL, SGOT \> 2.5 times ULN, Hgb \< 12.0 g/dL, creatinine \> 1.4 mg/dL, FSH \> 20 IU/L in women, or CD4 count \< 200~* Carpal tunnel syndrome~* Severe chronic illness or active malignancy or history of pituitary malignancy or history of colon cancer~* For men, history of prostate cancer or evidence of prostate malignancy by PSA \> 5ng/mL~* Prior history of hypopituitarism, head irradiation, or any other condition known to affect the GH axis~* positive beta-HCG (women only)~* Oral contraceptives, depo provera, or combined progesterone-estrogen injections, transdermal contraceptive patches, estrogen or progestin coated IUD's within 6 months of the study~* weight \< 110 pounds

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- GH 6mcg/kg/d (Type: EXPERIMENTAL): Recombinant human growth hormone 6mcg/kg SC once daily
- GH 2mg daily (Type: EXPERIMENTAL): Recombinant human growth hormone 2mg SC once daily
- Growth Hormone Releasing Hormone (Type: EXPERIMENTAL): Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Persistence of Oral Tolerance to Peanut

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All LEAP Study participants who are evaluable for peanut allergy at year 5 by LEAP (ClinicalTrials.gov ID NCT00329784) Study criteria.~* Parent or guardian willing to provide informed consent.~Exclusion Criteria:~* Unable or unwilling to comply with study intervention and procedures.~* Participation in other food allergy intervention trials.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Peanut avoidance after continuous peanut consumption (Type: EXPERIMENTAL): These participants were the peanut consumption group of the ITN032AD (LEAP) study
- Continued peanut avoidance (Type: EXPERIMENTAL): These participants were the peanut avoidance group of the ITN032AD (LEAP) study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: School Based Malaria Control in Ugandan Schoolchildren

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 6 - 14 years~* Pupils enrolled at participating school~* Willingness of the parent/guardian to provide consent~* Provision of assent by pupil (those above 8 years)~Exclusion Criteria:~* Known allergy or history of adverse reaction to study medications~* Intention of changing of schools during the follow-up period~* History (obtained from the parent/guardian) of any known serious chronic disease requiring frequent medical care

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Study Arms:
- Four monthly IPT (Type: EXPERIMENTAL): IPT give once a school term (every four months)
- Monthly IPT (Type: EXPERIMENTAL): IPT given every month
- Placebo (Type: PLACEBO_COMPARATOR): No active drug in the placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Mirogabalin for Central Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Spinal cord injury (SCI) due to trauma~* American Spinal Injury Association impairment scale A, B, C, or D~Exclusion Criteria:~* Other severe pain at screening or randomization, unrelated to central neuropathic pain after SCI, that may confound the assessment of central neuropathic pain after SCI~* Neurologic disorders at screening or randomization, unrelated to central neuropathic pain after SCI, that may confound the assessment of central neuropathic pain after SCI~* Major psychiatric disorders within 1 year prior to screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mirogabalin (Type: EXPERIMENTAL): The patients with creatinine clearance (CLcr) ≥ 60 mL/min: Mirogabalin 20 mg or 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose.~The patients with creatinine clearance (CLcr) 30 to \< 60 mL/min: Mirogabalin 10 mg or 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (14-weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consistent treatment for chronic, non-cancer-related pain with any full agonist opioid for at least 30 days prior to screening.~* Diagnosis of opioid-induced bowel dysfunction (OBD) as confirmed during the screening period.~* If patient has a history of chronic constipation, condition must have been exacerbated by initiation of opioid treatment.~* Use of prescribed or Over-the-Counter (OTC) medication that affects gastrointestinal motility (other than opioid therapy) must be discontinued during the study.~* If treated for clinical depression with Selective serotonin reuptake inhibitor (SSRIs), Serotonin-norepinephrine reuptake inhibitor (SNRIs), or Monoamine oxidase inhibitor (MAO) inhibitors, treatment must have been at a stable dose for at least 30 days prior to screening.~* Use of laxative and stool softeners (with the exception of approved rescue medications) must be discontinued while on study.~Exclusion Criteria:~* Treatment with opioid therapy for cancer-related pain, abdominal pain, scleroderma, and/or for the management of drug addiction.~* Patient has been treated for cancer in the past 5 years (with the exception of localized basal cell, squamous cell skin cancer, or in situ cancer that has been resected).~* Opioid dose adjustment (+/- 30%), and/or change in opioid agent or route of administration within 30 days of screening.~* Gastrointestinal or abdominal surgical procedures within 90 days prior to screening.~* Non-ambulatory patients, or those who are unable to eat/drink, take oral medications, or to hold down oral medications due to vomiting.~* Female patients of childbearing potential who are unable/unwilling to use protocol-specified method(s) of birth control and/or are pregnant, nursing, or plan to become pregnant or nurse during the study.~* Prior use of Amitiza, lubiprostone, SPI-0211, or RU-0211.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 0 mcg capsules twice daily (BID)
- Lubiprostone (Type: EXPERIMENTAL): 24 mcg capsules twice daily (BID)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete